Mr. Carbeau is a transformative healthcare leader who brings to Interleukin Genetics more than three decades of business expertise in the life science industries, with a proven track record of building high growth diagnostic and pharmaceutical businesses.
Mr. Carbeau began his career with Eli Lilly and Company. He founded CM Partners, a strategic life science consulting firm, and was a member of The Boston Consulting Group.
Mr. Carbeau served as Vice President of Corporate Development at OraPharma during its commercial launch of a periodontal therapeutic, a successful IPO, and the eventual sale of the company to Johnson & Johnson. He also served as President USA of Kinetic Concepts, President and CEO of HyperMed, and CEO of PolyRemedy.
Prior to joining Interleukin Genetics, Mr. Carbeau was Co-Founder and CEO of Diagnostyx, a technology company focused on intelligent drug infusion systems.
Mr. Carbeau holds a B.S. in Industrial Engineering from Penn State University and an MBA from the Wharton School of the University of Pennsylvania.
Prior to founding the company in 1986, Dr. Kornman was a Department Chair and Professor at the University of Texas Health Science Center at San Antonio.
Dr. Kornman holds academic appointments at Harvard University. He has also been a consultant and scientific researcher for many major oral care and pharmaceutical companies.
He has been awarded seven patents in the pharmaceutical area, has published three books and more than 125 scientific papers, and has lectured and consulted worldwide on the transfer of technology to clinical practice.
Dr. Kornman earned a B.A. in Economics from Duke University, a D.D.S. from Emory University, an M.S. in Periodontics from the University of Michigan, and a Ph.D. in Microbiology and Immunology from the University of Michigan.
Mr. DiPalma is Managing Director at Danforth Advisors, LLC, where he has served since April 2014.
He brings more than 25 years of experience in life sciences and healthcare, including founding two start-ups, working with venture-backed companies, subsidiaries of Fortune 100 firms and publicly traded companies, and his work with Danforth Advisors clients.
Previously, he served as the CFO of two public companies, and as CFO, COO, CEO or Director of eight privately held companies, in addition to his consulting clients.
In these roles, he has managed finance, accounting, corporate communications, human resources, information technology, facilities, business development, and manufacturing functions. Steve participated in the successful reorganization of Cambridge Biotech from Chapter 11 bankruptcy protection into Aquila BioPharmaceuticals, led the effort to take RXi public, and has extensive experience in international fund raising and corporate structuring.
He was formerly Chairman of the Board of Cognoptix, and is on the Board of Directors of Phytera, Inc. Mr. DiPalma received his B.S. from the University of Massachusetts-Lowell and his MBA from Babson College.
Mr. Toutain joined the Company in August 2016 and brings more than 25 years of commercial development, market access, and sales and marketing leadership with particular expertise in ultra-orphan drug and orphan oncology markets worldwide.
Prior to joining Interleukin, Mr. Toutain spent three years as a successful consultant to the biopharmaceutical industry addressing marketing strategy and access challenges.
Previously he headed Global Commercial Development for Sarepta Therapeutics, and served as General Manager for Alexion in Europe. Prior to these roles, Mr. Toutain held various commercial, marketing and product management positions with Alexion Pharmaceuticals, Celgene Corporation, and Johnson & Johnson.
Mr. Toutain received a Master of Business Administration from University of North Carolina, and a Master of Engineering in Biotechnology from University of Nancy II in France.